Results 31 to 40 of about 252,808 (266)

Diuretics as pathogenetic treatment for heart failure

, 2011
Maya GuglinUniversity of South Florida, Tampa, FL, USAAbstract: Increased intracardiac filling pressure or congestion causes symptoms and leads to hospital admissions in patients with heart failure, regardless of their systolic function.
Maya Guglin
core   +1 more source

Apparent treatment-resistant hypertension across the spectrum of heart failure phenotypes in the Swedish HF Registry

, 2022
Background: Hypertension is common in patients with heart failure (HF), but less is known about resistant hypertension. Objectives: This study sought to investigate apparent treatment-resistant hypertension (aTRH) in patients with HF in the ...
Jackson, Alice M.,, Jhund, PS, Petrie, Mark C.,, McMurray, JJV, Benson, L, Ulf Dahlström, Hage, C,, Dahlstrom, U, Pardeep S. Jhund, Lund, LH, Savarese, G,, Benson, Lina, Mark C. Petrie, Benson, Lina,, Lund, Lars H.,, Gianluigi Savarese, Dahlström, Ulf, John J.V. McMurray, McMurray, John J. V,, Petrie, Mark C., Jhund, Pardeep S.,, Savarese, Gianluigi, Petrie, MC, McMurray, John J.V., Lars H. Lund, Jackson, AM, Lund, Lars H., Hage, Camilla, Jackson, Alice M., Camilla Hage, Dahlström, Ulf,, Savarese, Gianluigi,, Hage, Camilla,, Jhund, Pardeep S., Alice M. Jackson, Lina Benson   +35 more
core   +1 more source

Are there etiology-specific risk factors for adverse outcomes in patients on Impella 5.5 support?Central MessagePerspective

JTCVS Open
Objectives: To identify possible etiology-specific differences in preoperative risk factors for major adverse events during Impella 5.5 support in patients with ischemic (ICM) and nonischemic cardiomyopathy (NICM).
Jean-Luc A. Maigrot, BS, Lucy Thuita, MS, Michael Z.Y. Tong, MD, MBA, Edward G. Soltesz, MD, MPH, Nicholas G. Smedira, MD, MBA, Shinya Unai, MD, Randall C. Starling, MD, MPH, Andrew Higgins, MD, David Moros, MD, Eugene H. Blackstone, MD, Aaron J. Weiss, MD, PhD   +10 more
doaj   +1 more source

Upregulation of Serum Sphingosine (d18:1)-1-P Potentially Contributes to Distinguish HCC Including AFP-Negative HCC From Cirrhosis

Frontiers in Oncology, 2020
BackgroundSerum sphingolipids are widely involved in the development of hepatocellular carcinoma (HCC). We investigated the serum sphingolipid profile in patients with HCC or cirrhosis and explored the potential diagnostic efficiency of serum ...
Yingying Jiang, Yingying Jiang, Cai Tie, Yang Wang, Yang Wang, Dandan Bian, Dandan Bian, Mei Liu, Mei Liu, Ting Wang, Ting Wang, Yan Ren, Yan Ren, Shuang Liu, Shuang Liu, Li Bai, Li Bai, Yu Chen, Yu Chen, Zhongping Duan, Zhongping Duan, Sujun Zheng, Sujun Zheng, Jinlan Zhang   +23 more
doaj   +1 more source

Algorithm for Treatment of Advanced Heart Failure

, 2013
Heart failure is a growing epidemic worldwide that confers a substantial medical and economic burden on our society. With the aging population and the improved treatment strategies made available over the last several decades including neurohormonal ...
Allareddy, Mrudula R., Deng, Mario C., Munagala, Mrudula, Richard K. Cheng, Cheng, Richard K., Farhana Latif, Shahzad, Khurram, Mrudula R. Allareddy, Latif, Farhana, Eugene C. DePasquale, DePasquale, Eugene C., Mario C. Deng, Khurram Shahzad   +12 more
core   +1 more source

A Bibliometric Analysis of Publications in Uremic Toxins From 1991 to 2024

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Uremic toxins are a growing area of research in nephrology, with significant implications in the progression and treatment of chronic kidney disease (CKD) and the management of end‐stage kidney disease (ESKD). This bibliometric analysis aims to evaluate the global research trends, key contributors, and the impact of publications in ...
Yuh‐Shan Ho, Karim M. Soliman, Wisit Cheungpasitporn, Wannasit Wathanavasin, Ahmed Daoud, Ahmed I. Kamal, Balázs Szamosfalvi, Tibor Fülöp   +7 more
wiley   +1 more source

Therapeutic Apheresis in Nigeria: A Multi‐Center Summary of Abstracts From the Inaugural Nigerian Society for Apheresis Scientific Meeting

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Therapeutic apheresis (TA) is an established treatment modality for hematologic, neurologic, and immunologic disorders, yet access remains severely limited in sub‐Saharan Africa. Donor apheresis, including platelet apheresis collection from healthy donors, represents an important complementary modality supporting blood product ...
Nosa Bazuaye, Chimezie Okwuonu, Evelyn Idam, Folasade Adelekan‐Popoola, Shakirat Gold‐Olufadi, Olufunto Olufela Kalejaiye, Abdullateef Ogala, Zinnah Aloziem, Blossom Amamchukwu, Patience Elimia, Mkpoikanabasi Obot‐Obot, Henry Mbakwe, Praises Maduagwuna, Olatunji Akinrodoye, Chiamaka Anyanwu, Benjamin Anyanwu, Adedamola Akinsiku, Oluwatoyin A. Akinsiku, Muzamil O. Hassan, Fatiu A. Arogundade, Olalekan E. Ojo, Homayemem Weli, Jesupelumi Adenihun, Aderemi Adelaja, Ebun Bamgboye, Olalekan Olatise, Ade E. Faponle, Ayoola Odeyemi, Michael Muoka, Stephen Asaolu, Qudrat Busari, Blessing Dawudu, Michael Naiyeju, Rasheed A. Balogun   +33 more
wiley   +1 more source

Heart 'omics' in AGEing (HOMAGE): design, research objectives and characteristics of the common database. [PDF]

, 2014
Heart failure is common in older people and its prevalence is increasing. The Heart 'omics' in AGEing (HOMAGE) project aims to provide a biomarker approach that will improve the early diagnosis of heart failure.
Rocca, Hans-Peter Brunner-La, Heymans, Stephane, Staessen, JA, Pocock, Stuart, Zannad, Faiez, Bauters, C, Brunner-La Rocca, Hans-Peter; id_orcid, Thijs, Lutgarde, Heymans, S, Cleland, J.G., Pocock, S, Staessen, Jan A., Mebazaa, A, Delles, C, Thijs, L, Masson, Serge, Bauters, Christophe, Kuznetsova, Tatiana, Tomaschitz, A, McDonald, K, Pinet, Florence, Collier, T, Mamas, Mamas, Pinet, F, Jacobs, Lotte, Mebazaa, Alexandre, Sever, P, Jin, Yu, Cleland, JG, Kuznetsova, T, Latini, Roberto, Rouet, P, Mamas, M, Cleland, John G F, Sever, Peter, Jin, Y, Latini, R, Delles, Christian, Rouet, Philippe, Brunner-La Rocca, Hans-Peter, Zannad, F, Brunner-La Rocca, HP, Jacobs, L, Pieske, Burket, Diez, Javier, Diez, J, Cleland, John GF, Masson, S, McDonald, Kenneth, Pieske, B, Staessen, Jan A, Cleland, John G.F., Rocca, HP, Collier, Timothy, Tomaschitz, Andreas, Pieske, Burkert   +55 more
core   +1 more source

Tacrolimus-Induced Thrombotic Microangiopathy in Orthotopic Heart Transplant Patients

JACC: Case Reports
Background: Thrombotic microangiopathy (TMA) is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ damage from microvascular injury.
Faysal Massad, MD, Tess Calcagno, MD, PharmD, Rochell Issa, MD, Kristen Tomaszewski, MD, Jennifer Reese, MSN, CNP, Randall C. Starling, MD, MPH, Andres Carmona Rubio, MD, Arianne Agdamag, MD   +7 more
doaj   +1 more source

Heart failure drug treatment [PDF]

The Lancet, 2019
Heart failure is the most common cardiovascular reason for hospital admission for people older than 60 years of age. Few areas in medicine have progressed as remarkably as heart failure treatment over the past three decades. However, progress has been consistent only for chronic heart failure with reduced ejection fraction.
Rossignol, Patrick, Hernandez, Adrian, Solomon, Scott, Zannad, Faiez   +3 more
openaire   +3 more sources